In October 2003, Verenium and Medarex announced a strategic partnership aimed at developing antibodies with enhanced functionality. Through a joint research effort, Verenium and Medarex planned to combine their respective capabilities in directed evolution and antibody biology. The companies cosponsored this project, and believe it may have broad applications in the field of therapeutic antibodies.
Medarex’s preclinical capabilities and expertise in immune cell receptor function are an excellent complement to Verenium’s antibody engineering capabilities to accelerate the development of optimized, highly-effective antibody-based drug candidates.
Medarex (Nasdaq: MEDX) is a biopharmaceutical company focused on the discovery and development of therapeutics to treat life-threatening and debilitating diseases. Medarex's UltiMAb™ Human Antibody Development System(SM) is a unique combination of human antibody technologies that Medarex believes enables the rapid creation and development of fully human antibodies to a wide range of potential disease targets for therapeutic antibody products, including products for the treatment of cancer, inflammation, autoimmune and infectious diseases. Medarex's product pipeline is based on a variety of therapeutic antibody products developed through the use of its UltiMAb™ technology. Medarex creates and develops fully human antibodies for itself and others, offering a full range of antibody related capabilities, including pre-clinical and clinical development supported by cGMP clinical manufacturing services. For more information about Medarex, visit www.medarex.com.
